2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 260-262
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Study Population, Animal Model
PAPER

659 Anti-leukemic activity and regulatory mechanisms of a novel MYC degrader WBC100 in T-cell acute lymphoblastic leukemia

Yile Zhou, MD, PhD, Dandan Zhao, PhD2, Huafeng Wang, MD3, Rongzhen Xu, PhD4, Guido Marcucci, MD5, Bin Zhang, PhD6, Jie Jin, MD7
1 Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, California, United States, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, California, United States
3 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
5 Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, California, United States
6 Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, California, United States
7 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Background: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive clonal hematologic malignancy that accounts for approximately 20% of all acute lymphoblastic leukemia (ALL) cases. In contrast to B-cell ALL (B-ALL), for which multiple targeted immunotherapies have transformed clinical outcomes, including CD19-directed chimeric antigen receptor (CAR) T-cell therapy, CD22-targeted antibody–drug conjugates (ADCs), and CD19/CD3 bispecific T-cell engagers (BiTEs), treatment options for T-ALL remain largely limited to intensive chemotherapy and hematopoietic stem cell transplantation (HSCT). Despite these approaches, patients with relapsed or refractory (R/R) T-ALL continue to have poor outcomes, and many are not candidates for intensive therapy because of age, comorbidities, or treatment-related toxicities. Consequently, there is a critical unmet need to develop effective, less toxic targeted therapies for patients with T-ALL, particularly those with R/R disease or those who are ineligible for intensive chemotherapy.

Methods: WBC100 is a novel, orally bioavailable molecular glue that selectively induces c-Myc protein degradation (Adv. Sci. 2022), and is currently being evaluated in a phase I clinical trial for acute myeloid leukemia. We conducted a comprehensive preclinical evaluation of WBC100 in T-ALL using in vitro and in vivo models.  Given the dependence of T-ALL cells on the anti-apoptotic proteins BCL-XL and MCL-1, together with molecular pathways identified by RNA sequencing following WBC100 treatment, we further investigated the therapeutic efficacy of combining WBC100 with pharmacologic inhibition of BCL-XL or MCL-1.

Results: MYC is a key driver of T-ALL. We confirmed that MYC was highly expressed in T-ALL cell lines, primary patient samples, and published available datasets. Consistent with its mechanism of action, the MYC degrader WBC100 demonstrated potent antileukemic activity against T-ALL cell lines and primary patient samples in vitro. In vivo, WBC100 0.4mg/kg/day significantly reduced tumor burden and prolonged survival in two T-ALL cell line–derived xenograft (CDX) models when compared with control groups. In the Jurkat CDX model, median survival increased from 37.5 days in controls to not reached after >120 days with WBC100 treatment (P = 0.0025). In the CCRF-CEM CDX model, median survival increased from 27 to 44 days (P = 0.0031). Therapeutic efficacy was further validated in two patient-derived xenograft (PDX) models, where median survival increased from 43 to 70.5 days in PDX-1 (P = 0.0122) and from 44 to 84.5 days in PDX-2 (P = 0.0108).

RNA sequencing of WBC100-treated T-ALL cells demonstrated suppression of MYC-driven transcriptional programs, including MYC targets, E2F targets, G2/M checkpoint, and mTORC1 signaling. In parallel, WBC100 treatment induced upregulation of adaptive stress-response, most notably oxidative phosphorylation. Based on these findings and the known dependence of T-ALL cells on the anti-apoptotic proteins BCL-XL and MCL-1, we evaluated rational combination strategies. WBC100 exhibited strong synergistic antileukemic activity in vitro when combined with the BCL-XL inhibitor navitoclax or homoharringtonine, an agent that suppresses MCL-1 expression. Both combinations significantly enhanced apoptosis compared with either agent alone. Evaluation of these combination therapies in vivo is ongoing.

Conclusions: WBC100 exhibits potent antileukemic activity against T-ALL by selectively degrading MYC and suppressing MYC-dependent transcriptional programs. WBC100 demonstrated robust efficacy across multiple preclinical T-ALL models, including primary patient samples, CDX, and PDX models. Furthermore, rational combinations with BCL-XL or MCL-1 inhibition produced synergistic antileukemic activity in vitro. Collectively, these findings support the further clinical development of WBC100 as both a monotherapy and a rational combination strategy for patients with T-ALL.

Yile Zhou, MD, PhD: No relevant conflicts of interest to declare.